skip to content

Trading statements

Skyepharma sees strong growth in FY 2016 revenues

18 May 2016 09:16

Skyepharma said its overall trading performance to end-April has been good and that directors continue to expect strong growth in revenues for FY 2016 compared with FY 2015.

CEO Peter Grant said the company remained on track to deliver further strong growth in revenues in 2016, with increased demand for flutiform, Pacira's EXPAREL and the GSK Ellipta products incorporating Skyepharma technology.

"Important clinical studies to expand the successful flutiform franchise are nearing completion and the Group is also making good progress with its promising pipeline of inhalation and oral products and technologies," he said in a statement.

"Following the overwhelming shareholder vote earlier this month in support of the Board's recommended all-share merger with Vectura, we look forward to the future with confidence."

At 9:16am:

(LON:SKP) SkyePharma PLC share price was -2p at 469.75p

Story provided by StockMarketWire.com

Related Company: SKP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.